top of page

What Have Human Studies Discovered About Beta-Caryophyllene?

7 days ago
8 min read

Updated: 5 days ago

Cloves and black pepper alongside molecular imagery and a clinical research discussion illustrating human beta-caryophyllene studies

Blair Medical Group | Research reviewed November 9, 2026


What happens when scientists take beta-caryophyllene out of the laboratory and study it in real people? The answers are becoming more interesting.

Beta-caryophyllene (BCP) is a plant-derived sesquiterpene found in cloves, black pepper and other botanicals. It attracted scientific interest after researchers identified its ability to activate cannabinoid type 2 (CB2) receptors, which participate in immune and inflammatory signaling.

Human studies have since investigated BCP in digestive symptoms, eating behavior, exercise-related muscle soreness, joint function, neuropathy and absorption. The findings reveal measurable responses in several settings, but the details matter: some researchers tested BCP itself, others tested combinations containing BCP, and others measured how different delivery systems change its absorption.

The central discovery is that human BCP research is no longer limited to its biological mechanism. Researchers are beginning to measure what happens after BCP is administered to people.


What have researchers actually studied in humans?

Human beta-caryophyllene research includes randomized controlled trials, observational studies and pharmacokinetic investigations. Each type of study answers a different question.

A randomized trial can compare an intervention with a control to evaluate a measured outcome. An observational study can identify changes occurring during use of a particular preparation. A pharmacokinetic study can measure how much of a compound enters the bloodstream and how quickly.

These differences are especially important for BCP because it has been investigated in pure or single-ingredient preparations, combinations with other active ingredients, and specialized delivery systems.

Human BCP research at a glance

Research topic

Participants

Study design

Principal observation

Digestive symptoms and H. pylori

66

Randomized, placebo-controlled

Changes in nausea, epigastric pain and IL-1β

Food-addiction questionnaire outcomes

52

Randomized, placebo-controlled

Improvement in food-addiction scores

Exercise-related muscle soreness

20

Randomized crossover, placebo-controlled

Reduced perceived soreness with Rephyll

Oral BCP absorption

24

Randomized crossover

Higher systemic exposure with a self-emulsifying formulation

Knee osteoarthritis

38

Double-blind comparative study

Changes in pain and function with a multi-ingredient formulation

Painful diabetic neuropathy

25

Observational

Changes in reported pain and nerve-conduction measures

Inhaled BCP and stress responses

48

Experimental odor-exposure groups

Changes in anxiety ratings and physiological responses

These selected studies illustrate the range of human investigations. They also show why the formulation and research design are essential to interpreting the results.


A digestive study reveals an intriguing connection to inflammatory signaling

One of the more direct human investigations was published in 2019. Researchers enrolled 66 people with Helicobacter pylori infection in an eight-week randomized, double-blind, placebo-controlled study.

Half received 126 mg of beta-caryophyllene daily, while the other half received placebo. The researchers assessed digestive symptoms, infection-related measurements and circulating inflammatory cytokines.

Three findings stood out: participants receiving BCP reported improvements in nausea and epigastric pain, or upper-abdominal discomfort, and serum interleukin-1β (IL-1β), a molecule involved in inflammatory signaling, decreased.

The investigation also measured H. pylori infection status. Complete bacterial eradication was not observed in either group, and the main infection-related measures did not show a significant improvement.

This contrast is revealing. The researchers detected changes in symptoms and a circulating inflammatory mediator even though they did not establish eradication of the infection. It provides a human research example connecting BCP administration with measurable biological and symptom-related outcomes.


Can beta-caryophyllene influence eating-related behavior?

Another controlled study investigated a less obvious research question: whether beta-caryophyllene affects eating-related behavior. In 2022, researchers enrolled 52 women with obesity who met the investigation's criteria for food addiction.

Participants received either a daily BCP softgel or placebo for eight weeks. The study measured food-addiction questionnaire scores, body composition, appetite, dietary intake, mental-health measures and several circulating biological markers.

The BCP group demonstrated a statistically significant improvement in the Yale Food Addiction Scale score compared with placebo. Yet several other measured outcomes did not differ significantly between groups, including body composition, anthropometric measurements, appetite and dietary intake.

That distinction helps clarify what the study found. The principal reported signal concerned a behavioral questionnaire, rather than a demonstrated change in body weight or overall food consumption. The investigators opened an interesting question about how BCP may interact with biological systems involved in eating behavior.


What happens when BCP is investigated after exercise?

Intense or unfamiliar exercise can produce delayed-onset muscle soreness, often called DOMS. The experience involves discomfort that develops after exercise, frequently accompanied by tenderness and temporary changes in muscular strength or flexibility.

Researchers have studied a specialized liposomal beta-caryophyllene preparation called Rephyll in this setting. A 2020 randomized, double-blind, placebo-controlled crossover trial enrolled 20 healthy young men.

Participants underwent an exercise protocol designed to produce muscle soreness. Investigators assessed subjective pain, strength, flexibility and selected markers of muscle stress. The Rephyll preparation was associated with improvements in reported soreness and selected recovery measurements.

Researchers also examined its formulation technology, designed to encapsulate BCP and improve characteristics such as stability and delivery. The result brings two questions together: how a compound is delivered and what investigators observe after administration. Because this study used Rephyll, its clinical findings describe that intervention.

Read the original study: Amalraj et al., 2020 — Liposomal β-Caryophyllene and Delayed-Onset Muscle Soreness. DOI: 10.1021/acsomega.0c03456.

For more context, explore Beta-Caryophyllene and Muscle Recovery.


What have human studies found about joint health?

A 2023 clinical investigation examined a combination of hemp seed oil and terpenes in 38 participants with knee osteoarthritis. The study compared hemp seed oil with a formulation containing hemp seed oil alongside beta-caryophyllene, myrcene and ginger extract.

After 45 days, investigators reported improvement in several pain and functional assessments in both groups. Selected measures, including pain ratings and knee-function scores, showed greater improvement in the group receiving the combination.

These findings concern outcomes experienced by people living with knee osteoarthritis, but they also illustrate an important feature of combination research. Investigators studied several ingredients together, so the contribution of any single component cannot be separated from the complete preparation.

That leaves a useful question for further studies: how much of the observed response is attributable to BCP itself?


What about BCP and neuropathic pain?

Painful diabetic neuropathy involves changes in peripheral nerve function associated with diabetes. This is an interesting area of investigation because sensory signaling, metabolic processes and neuroimmune activity can interact.

A 2018 observational study followed 25 participants with painful diabetic distal symmetric polyneuropathy. The participants received a nutraceutical combination containing beta-caryophyllene, myrrh, carnosic acid and palmitoylethanolamide (PEA).

After 16 weeks, researchers reported reductions in pain scores and improvement in selected nerve-conduction measurements. These were changes in patient assessments and physiological tests, rather than solely experimental markers.

The study was observational and involved multiple ingredients. Its findings therefore describe the combined preparation and provide a direction for more controlled investigation.


One of the clearest human findings concerns absorption

If two preparations contain the same amount of BCP, will the body absorb them in the same way? A 2022 investigation tested that question directly.

Researchers enrolled 24 healthy adults in a randomized, double-blind crossover trial comparing ordinary BCP oil with a self-emulsifying preparation developed using VESIsorb technology. Both preparations supplied 100 mg of BCP.

Investigators collected blood samples over time to measure concentrations and calculate pharmacokinetic parameters. The self-emulsifying formulation produced approximately 2.0–2.2 times greater overall measured exposure, approximately 3.6 times higher peak blood concentration, and faster time to peak concentration: around 1.43 hours, compared with 3.07 hours for BCP oil.

These results show how strongly formulation design can influence the absorption of the same plant compound. The study did not evaluate symptom relief or disease outcomes. Instead, it answered how delivery technology affects the amount of BCP reaching the bloodstream.


A different research route: inhalation and stress responses

Not every human BCP investigation uses an oral supplement. In 2024, researchers studied 48 participants assigned to inhalation groups receiving BCP, citral, linalool or an odorless control.

Participants completed tasks designed to induce mental stress. Investigators evaluated anxiety ratings, heart rate, brain electrical activity and facial-expression measures. BCP inhalation was associated with changes in anxiety ratings and selected physiological responses.

This provides a perspective on olfactory exposure and measurable stress responses. Because the route was inhalation, these findings should be interpreted separately from clinical studies using oral BCP.

An additional small study involving 19 women measured hormone concentrations following exposure to BCP vapor. Researchers observed increased salivary testosterone but did not establish a corresponding improvement in sexual function. Read Tarumi and Shinohara, 2020 — Olfactory Exposure to β-Caryophyllene.


What connects these human studies?

At first, digestive symptoms, food-addiction questionnaires, muscle soreness, joint function and absorption may appear to have little in common. The studies share a scientific foundation: researchers are investigating how beta-caryophyllene interacts with biological systems and what changes can be measured in human participants.

BCP's interaction with CB2 receptors offers an important starting point. CB2 signaling is involved in immune and neuroimmune biology and has been examined extensively in laboratory and animal research.

Human studies add measured symptoms, behavior, physiological responses and pharmacokinetics to that foundation. A blood concentration differs from a pain score. An inflammatory cytokine differs from a diagnosis. A controlled study of BCP differs from an observational study of several ingredients.

Blair Medical Group's evidence review uses study design, intervention and measured endpoint as the basis for interpreting these findings. This approach helps readers understand what researchers observed and what can reasonably be inferred.

For broader biological context, read Beta-Caryophyllene and Metabolic Health.


Where does human BCP research go next?

The existing literature points toward several questions: BCP-only preparations in larger controlled trials, consistent outcome measures across study populations, and how absorption relates to measured biological activity.

Researchers can compare different oral delivery systems to determine how formulation characteristics affect exposure. Longer investigations could provide additional information about the durability of measured outcomes and safety under defined conditions.

The next stage of research will be especially valuable when studies connect a verified BCP formulation, a measurable level of exposure and a clearly defined human outcome. That is how a growing group of studies can become a more coherent evidence base.


Frequently Asked Questions

Yes. Published human research includes randomized clinical trials, observational studies, inhalation experiments and pharmacokinetic investigations. The populations, preparations and outcomes differ among studies.

Some investigations tested BCP-containing single-ingredient preparations against placebo, including the digestive-symptom and food-addiction studies. Other investigations used combinations or specialized delivery technologies.

Improved absorption means that a formulation produced greater or faster measured systemic exposure under the study conditions. Clinical studies are required to determine whether those differences translate into particular human outcomes.

A BCP-only controlled study can more directly investigate the effect of that intervention. A combination study measures the response to several ingredients together, making individual ingredient contributions more difficult to isolate.

The studies discussed here used the preparations identified by their investigators. Their results describe those interventions and should be distinguished from clinical evidence for individual BCPlus finished products.

The next chapter in human beta-caryophyllene research

Human studies have begun connecting beta-caryophyllene with measured outcomes in digestive function, behavior, muscle recovery, joint health, nerve-related symptoms and formulation absorption.

The most useful lesson is the importance of asking precise questions: What preparation was tested? Who participated? What changed? How was it measured? Those questions turn individual studies into meaningful scientific understanding and help guide the next generation of BCP research.


Explore BCPlus formulations developed by Blair Medical Group

Blair Medical Group develops physician-formulated BCPlus supplements using delivery approaches selected for the properties of beta-caryophyllene. The collection includes different formats designed for different preferences and applications.

Because formulation is central to the human research reviewed above, readers may be especially interested in BMG's oral BCP preparations. Explore current product information, ingredient lists and delivery formats to understand how each formulation is designed.


BCPlus Oral Liposomal Drops 60 mL

This liposomal formulation is presented for product discovery and comparison. The VESIsorb and Rephyll research involved different preparations.

BCPlus Oral Liposomal Drops 60ml
Buy Now

Research reviewed November 9, 2026. Article type: selected narrative review. Publisher: Blair Medical Group. Medical review: pending.

Comments


bottom of page